DIAGNOSTIC TEST TO EVALUATE IRRITABLE BOWEL SYNDROME

肠易激综合征是最常见的胃肠道症状。 患者为此寻求医疗护理，可能会遭受多达20 在某种程度上占总人口的百分比。研究表明， 肠易激综合征患者构成了很大一部分 初级保健医生执业(约占所有患者的12% 就诊)，占所有胃肠道疾病的25%以上 推荐人。据估计，每年有240-350万人次的医生就诊 年份与IBS有关。肠易激综合征已被诊断为排斥 使患者有义务接受一系列昂贵的测试，例如 内窥镜检查，全血计数，肝功能检查，血清 电解质、血沉、尿液分析、大便 培养和X光检查。如果这些研究都是否定的，那么 肠易激综合征的诊断可由患者决定。通常情况下，患者不是 感到满意，并向另一位重复这种情况的医生寻求治疗 昂贵的研究。我们发现一种廉价且非侵入性的 肠音的计算机化时间序列分析可以为 首次以阳性结果诊断IBS的实用试验 正常受试者或克罗恩病患者。 此二期项目的目标是确认临床 这项测试在一大批预期人群中的准确性和有用性 未确诊的病人表现为腹痛。此外，我们 我将调查一些可能影响测试的基本参数 结果，如昼夜节律和女性的月经周期 病人。 建议的商业应用： 本产品将用于肠易激综合征的诊断 它困扰着美国多达20%的人口 各州。主要客户将是胃肠病专家，内部 医学和家庭执业医生，以及医院和 诊所。主要的软件产品将非常经济和 应该会在总体资源利用率方面带来相当大的节省。 这一经济激励措施以及患者利益将导致 成功的商业开发。

Irritable bowel syndrome is the most common gastrointestinal complaint for which patients seek medical care, and may afflict as much as 20 percent of the population to some degree. Studies indicate that patients with irritable bowel syndrome constitute a large portion of a primary care physician's practice (about 12 percent of all patient visits) and account for more than 25 percent of all gastrointestinal referrals. It is estimated that 2.4-3.5 million physician visits per year are related to IBS. IBS has been a diagnosis of exclusion obligating the patient to undergo a series of expensive tests such as endoscopy, complete blood counts, liver function tests, serum electrolytes, erythrocyte sedimentation rate, urine analysis, stool cultures and X-ray studies. If these studies are all negative, the diagnosis of IBS may be given to the patient. Often the patient is not satisfied and seeks care from another physician who repeats this expensive study. We have found that an inexpensive and non-invasive computerized time series analysis of bowel sounds can provide for the first time a practical test with a positive result distinguishing IBS patients from normal subjects or patients with Crohn's disease. The objective of this Phase II project is to confirm the clinical accuracy and usefulness of this test with a large prospective group of undiagnosed patients presenting with abdominal pain. In addition, we will investigate some basic parameters which may influence the test results, such as circadian rhythm and the menstrual cycle in female patients. PROPOSED COMMERCIAL APPLICATION: This product will be used in the diagnosis of irritable bowel syndrome which afflicts as much as 20 percent of the population in the United States. The primary customers will be gastroenterologists, internal medicine and family practice physicians, as well as hospitals and clinics. The primarily software product will be very economical and should result in quite large savings in overall resource utilization. This economical incentive along with patient benefit will result in a successful commercial development.